ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2258

Real-World Evidence Linking Health-Related Quality of Life to Work Outcomes in Patients with Rheumatoid Arthritis

Vibeke Strand1, Mark Kosinski2, Regina Rendas-Baum2, David Brooks3 and Rita Ganguly4, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2Optum, Inc, Eden Prairie, MN, 3GlaxoSmithKline, Philadelphia, PA, 4GlaxoSmithKline, Collegeville, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disability, quality of life, Rheumatoid arthritis (RA) and work

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Patient Outcomes, Preferences, and Attitudes Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Evaluating health-related quality of life (HRQoL) scores is a key component of the management of rheumatoid arthritis (RA) and evaluation of treatment efficacy.  There is a need to further understand how observed differences in these scores translate into impact on work-related outcomes.  The objective of these analyses was to establish a quantitative link between reported HRQoL and work outcomes of RA patients.

Methods: Patient data was obtained from 2 independent databases: QualityMetric’s 2009 PRO Norming Survey (QMPRONS) and the Medical Expenditure Panel Survey (MEPS).  Physical and Mental Component Summary (PCS and MCS) scores of Short Form-12v2 Health Survey (SF-12v2; captured in MEPS) and Short Form-36v2 Health Survey (SF-36v2; captured in QMPRONS) assessed HRQoL.  Work outcomes were evaluated using the following endpoints: inability to work due to disability, lost days of work/housework, self-rated job performance, and presence of serious cognitive difficulties.  Logistic regression models analyzed binary outcomes (inability to work, self-rated job performance [low vs medium/high], and presence of cognitive difficulties).  A zero-inflated Poisson model was used to analyze the relationship between HRQoL and lost days of work/housework.  A 5-point difference was used to illustrate the impact of lower HRQoL on work outcomes.

Results:   Lower PCS and MCS scores were significantly associated with inability to work due to health (lower PCS: odds ratio [OR], 2.42; 95% confidence interval [CI], 2.14-2.74; lower MCS: OR, 1.40; 95% CI, 1.28-1.52; both P <0.0001).  Furthermore, lower SF-12v2 summary scores were significantly associated with increased numbers of missed days of work/housework (lower PCS: 4.4 vs 1.3 missed days for scores of 40 vs 45, respectively; P <0.0001; lower MCS: 3.6 vs 1.6 missed days for scores of 40 vs 45, respectively; P = 0.0002).  For SF-36v2 MCS, a lower score was associated with greater odds of low job performance among employed patients (OR, 1.58; 95% CI, 1.34-1.85; P <0.0001), although a lower PCS score did not significantly increase odds of reporting low job performance.  Lower SF-12v2 scores were significantly associated with increased risks for serious cognitive difficulties in both employed and all patients (all P <0.0001; Figure).

Conclusion: Low physical and mental health is associated with an increased inability to work and increased number of missed days of work.  These analyses demonstrate that lower scores significantly impact work outcomes and underscore the importance of both summary measures in terms of measuring the impact of RA.

Figure. Increase in the odds of presence of cognitive difficulties associated with a 5-point lower SF-12v2 score.

SF-12v2, Short Form-12v2 Health Survey; PCS, physical component summary; MCS, mental component summary; CI, confidence interval.


Disclosure: V. Strand, AbbVie, Amgen, AstraZeneca, Biogen Idec, Boehringer Ingelheim, Celltrion, Crescendo, Genentech/Roche, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sanofi, and UCB, 5; M. Kosinski, Optum, Inc, 3; R. Rendas-Baum, Optum, Inc, 3; D. Brooks, GlaxoSmithKline, 3,GlaxoSmithKline, 1; R. Ganguly, GlaxoSmithKline, 1,GlaxoSmithKline, 3.

To cite this abstract in AMA style:

Strand V, Kosinski M, Rendas-Baum R, Brooks D, Ganguly R. Real-World Evidence Linking Health-Related Quality of Life to Work Outcomes in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/real-world-evidence-linking-health-related-quality-of-life-to-work-outcomes-in-patients-with-rheumatoid-arthritis/. Accessed September 22, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-evidence-linking-health-related-quality-of-life-to-work-outcomes-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology